Citadel Advisors
LYEL icon

Citadel Advisors’s Lyell Immunopharma LYEL Stock Holding History

Citadel Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
17,000
+5,000
+42% +$90.5K ﹤0.01% 11643
2026
Q1 		$241K Buy
+12,000
New +$281K ﹤0.01% 10993
2025
Q2 		– Sell
-145
Closed -$1.56K – 14000
2025
Q1 		$1.56K Sell
145
-240
-62% -$2.94K ﹤0.01% 14120
2024
Q4 		$4.93K Sell
385
-520
-57% -$10.3K ﹤0.01% 13891
2024
Q3 		$25K Buy
905
+775
+596% +$22.8K ﹤0.01% 12601
2024
Q2 		$3.77K Buy
+130
New +$6.19K ﹤0.01% 13549
2024
Q1 		– Sell
-65
Closed -$2.52K – 15117
2023
Q4 		$2.52K Sell
65
-445
-87% -$16K ﹤0.01% 13687
2023
Q3 		$15K Buy
510
+495
+3,300% +$23.5K ﹤0.01% 12844
2023
Q2 		$954 Sell
15
-35
-70% -$1.94K ﹤0.01% 14013
2023
Q1 		$2.36K Sell
50
-85
-63% -$4.54K ﹤0.01% 14161
2022
Q4 		$9.37K Buy
+135
New +$13.4K ﹤0.01% 13688

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Citadel Advisors's LYEL Position: Q2 2026 in Review

Citadel Advisors reduced its Lyell Immunopharma (LYEL) stake by 95% in Q2 2026, selling an estimated $6.57M and leaving 18,695 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #11425.

Citadel Advisors first reported a position in LYEL in Q2 2021 and has held it in 19 quarters since. The position peaked at $9.99M in Q4 2025. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Citadel Advisors held 18,695 shares of Lyell Immunopharma worth $263K as of Q2 2026.
  • Citadel Advisors sold 362,767 Lyell Immunopharma shares in Q2 2026, an estimated $6.57M.
  • Lyell Immunopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11425 holding.
  • Citadel Advisors first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Lyell Immunopharma position peaked at $9.99M in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.